| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | -53K | -112% |
| Gross Profit | -53K | -112% |
| Cost Of Revenue | - | - |
| Operating Income | -1.8MM | -28% |
| Operating Expenses | 1.7MM | -41% |
| Net Income | -3.4MM | +40% |
| R&D | - | - |
| G&A | - | - |
| Marketing | - | - |
| Interest Expense | 20K | -56% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BOCA RATON, Fla., March 29, 2024--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
In this article, we will be taking a look at the 25 countries with highest abortion rates. If you do not want to learn about the global pregnancy care products market, head straight to the 5 Countries With Highest Abortion Rates. The prevalence of abortion rates varies significantly across nations, shedding light on complex socio-political, […]
In this article, we will be taking a look at the 12 best prenatal vitamins for pregnant women. If you are not interested in reading about the market insights, head straight to the 5 Best Prenatal Vitamins For Pregnant Women. Discovering the best prenatal vitamins is crucial for the well-being of expectant mothers and their growing babies. […]
BOCA RATON, Fla., November 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023.
BOCA RATON, Fla., August 14, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023.
BOCA RATON, Fla., May 15, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023.
TherapeuticsMD (TXMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BOCA RATON, Fla., April 07, 2023--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022.
BOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products
Women's health care venture TherapeuticsMD will terminate its entire team of 212 employees by the end of the year, according to a Worker Adjustment and Retraining Notification notice submitted Dec. 6. The layoffs come after the cancellation of the pharmaceutical company's planned merger with Athene Merger, an affiliate of private equity firm EW Healthcare Partners.